Draft concept paper on the revision of the reflection paper on non-clinical and clinical development of similar biological medicinal products containing recombinant interferon alpha or pegylated recombinant interferon alpha

  • Email
  • Help

Document details

Download document Draft concept paper on the revision of the reflection paper on non-clinical and clinical development of similar biological medicinal products containing recombinant interferon alpha or pegylated recombinant interferon alpha
Reference number EMA/CHMP/BMWP/693108/2015
Status draft: consultation open
First published 04/01/2016
Last updated 04/01/2016
Consultation start date 04/01/2016
Consultation end date 31/03/2016
Email address for submissions bmwp.secretariat@ema.europa.eu

Summary

The current reflection paper on similar medicinal products containing recombinant interferon alpha provides recommendations for the non-clinical and clinical development of recombinant interferon alpha claimed to be similar to a reference product already authorised in the European Union (EU). This reflection paper was published in April 2009. Since then, no products containing biosimilar interferon alpha have been licensed in the EU. It is proposed to update the guidance based on the experience gained with marketing authorisation applications of reference products and scientific advice on biosimilar interferon alpha.